Why it matters: The biotech company’s expansion to a second lobbying firm signals xenotransplantation is moving from experimental to commercial reality. eGenesis previously relied solely on Invariant LLC but added King & Spalding LLP as regulatory frameworks evolve and competition intensifies.
By the Numbers: eGenesis spent $270,000 on lobbying through Invariant LLC from January to July 2025. The company registered King & Spalding on August 29, 2025, assigning David Joseph Farber as lead lobbyist. Farber brings extensive healthcare experience, including work with Kidney Transplant Collaborative Inc. and multiple pharmaceutical clients on Medicare coverage issues.
Broader Context: The xenotransplantation field reached a historic milestone in March 2024 when Massachusetts General Hospital performed the first successful pig kidney transplant into a living human using an eGenesis organ. The FDA approved the company’s clinical trials in February 2025, creating direct competition with United Therapeutics, which also received trial approval. eGenesis raised $191 million in September 2024 to advance its lead product EGEN-2784.
The Agenda: The lobbying registration doesn’t specify particular legislation or issues. However, eGenesis focuses on “educating lawmakers and policymakers on xenotransplantation” according to previous filings. The timing aligns with FDA development of comprehensive regulatory frameworks for genetically modified pig organs.
Competitive Landscape: United Therapeutics received FDA approval for the first formal xenokidney clinical trial, enrolling up to 50 participants. Their pig kidney uses 10 gene edits compared to eGenesis’s 69 modifications. Both companies are racing to be first to market in addressing the organ shortage crisis affecting over 90,000 kidney transplant candidates.
Between the Lines: Congress is actively addressing organ shortages through multiple bills, including the Charlotte Woodward Organ Transplant Discrimination Prevention Act and tax credit proposals for organ donors. The OPTN Fee Collection Authority Act could facilitate xenotransplant integration into existing allocation systems. Farber’s Medicare expertise becomes crucial as the industry needs reimbursement pathways. Legislation like the Living Organ Donor Tax Credit Act and End Kidney Deaths Act also recognize the organ shortage crisis.
The Bottom Line: eGenesis’s lobbying expansion reflects xenotransplantation’s transition from science experiment to potential medical standard. With clinical trials underway and regulatory frameworks developing, the company needs sophisticated advocacy to shape policies that could determine commercial success in addressing the organ shortage crisis.
Spot something wrong? Report an issue with this article